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Abstract: Objective Case series with different clinical presentations indicating central nervous system
(CNS) involvement in coronavirus disease 2019 (COVID-19) have been published. Comprehensive work-
ups including clinical characteristics, laboratory, electroencephalography (EEG), neuroimaging and cere-
brospinal fluid (CSF) findings are needed to understand the mechanisms. Design We evaluated 32 con-
secutive patients with severe SARS-CoV-2 infection treated at a tertiary care centre from March 09 to
April 03, 2020 for concomitant severe central nervous system (CNS) symptoms occurring during their
critical disease state. Those with CNS disorders were examined in detail regarding clinical characteristics
and undergoing additional examinations, e.g. computed tomography (CT), magnetic resonance imaging
(MRI), (EEG), (CSF) analysis and autopsy if they had died. Results Of 32 critically ill patients with
COVID-19 eight (18%) had severe CNS involvement (mean [SD] age, 67.6 [6.8] years; seven men; two
patients died). All eight patients had cardiovascular risk factors, most frequently arterial hypertension.
Two patients presented with lacunar ischemic stroke and one with status epilepticus in the early phase.
As most common presentation, six patients presented with prolonged impaired consciousness after termi-
nation of analgosedation. In all but one with delayed wake-up, neuroimaging or autopsy showed multiple
cerebral microbleeds, in three of them with additional subarachnoid haemorrhage and in another two with
additional small ischemic lesions. In three patients intracranial vessel wall sequence MRI was performed,
for the first time to our knowledge. All cases showed contrast-enhancement of vessel walls in large and
middle-sized cerebral arteries, suggesting vascular wall pathologies with an inflammatory component.
CSF analysis showed normal cells counts and chemistry. RT-PCRs for SARS-CoV-2 in CSF were all
negative, and no intrathecal SARS-CoV-2 specific IgG synthesis was detectable. Conclusions CNS disor-
ders are common in patients with severe COVID-19. Different mechanisms might be involved. Besides
unspecific encephalopathy and encephalitic syndromes, large vessel strokes might occur early after disease
onset. In a later phase, microbleeds and microinfarctions indicate potential CNS small vessel disease.
MRI vessel wall contrast enhancement suggests cerebral vascular wall pathologies with an inflammatory
component. CNS disorders associated with COVID-19 may lead to long-term disabilities aggravating
socio-economic damage. The mechanisms have to be investigated urgently in order to develop preventive
and therapeutic neuroprotective strategies.
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Case series with different clinical presentations indicating central nervous system (CNS) involvement in coronavirus disease 2019 (COVID-19) have
been published. Comprehensive work-ups including clinical characteristics, laboratory, electroencephalography (EEG), neuroimaging and cerebrospinal
 uid (CSF)  ndings are needed to understand the mechanisms.
Design
We evaluated 32 consecutive patients with severe SARS-CoV-2 infection treated at a tertiary care centre from March 09 to April 03, 2020 for
concomitant severe central nervous system (CNS) symptoms occurring during their critical disease state. Those with CNS disorders were examined in
detail regarding clinical characteristics and undergoing additional examinations, e.g. computed tomography (CT), magnetic resonance imaging (MRI),
(EEG), (CSF) analysis and autopsy if they had died.
Results
Of 32 critically ill patients with COVID-19 eight (18%) had severe CNS involvement (mean [SD] age, 67.6 [6.8] years; seven men; two patients died). All
eight patients had cardiovascular risk factors, most frequently arterial hypertension. Two patients presented with lacunar ischemic stroke and one with
status epilepticus in the early phase. As most common presentation, six patients presented with prolonged impaired consciousness after termination of
analgosedation. In all but one with delayed wake-up, neuroimaging or autopsy showed multiple cerebral microbleeds, in three of them with additional
subarachnoid haemorrhage and in another two with additional small ischemic lesions. In three patients intracranial vessel wall sequence MRI was
performed, for the  rst time to our knowledge. All cases showed contrast-enhancement of vessel walls in large and middle-sized cerebral arteries,
suggesting vascular wall pathologies with an in ammatory component. CSF analysis showed normal cells counts and chemistry. RT-PCRs for SARS-
CoV-2 in CSF were all negative, and no intrathecal SARS-CoV-2 speci c IgG synthesis was detectable.
Conclusions
CNS disorders are common in patients with severe COVID-19. Different mechanisms might be involved. Besides unspeci c encephalopathy and
encephalitic syndromes, large vessel strokes might occur early after disease onset. In a later phase, microbleeds and microinfarctions indicate potential
CNS small vessel disease. MRI vessel wall contrast enhancement suggests cerebral vascular wall pathologies with an in ammatory component. CNS
disorders associated with COVID-19 may lead to long-term disabilities aggravating socio-economic damage. The mechanisms have to be investigated
urgently in order to develop preventive and therapeutic neuroprotective strategies.
Introduction
Neurologic disorders in COVID–19 have been reported in 36.4% of the patients of the Wuhan series (1). Recently, more and more individual case
descriptions with central nervous system (CNS) involvement have been published in Asia, Europe and North America (2–11).
Comprehensive workups of as many cases as possible are needed to understand a potential “Neuro-COVID–19” disease and, in a next step, to develop
preventive as well as therapeutic strategies.
Below eight cases of critically ill patients with the primary diagnosis of severe COVID–19 pneumonia and subsequent neurologic complications
examined with electroencephalography (EEG), neuroimaging and cerebrospinal  uid (CSF) analysis are presented. The  ndings are assigned to
previously published case reports.
Methods
Study Design and Participants
We retrospectively analysed consecutive patients with severe COVID–19 treated at the Institute of Intensive Care Medicine, University Hospital Zurich
from March 09, 2020 to April 03, 2020. The patients were evaluated for concomitant severe central nervous system (CNS) symptoms occurring during
their critical disease state. Furthermore, the Institute of Intensive Care Medicine of the University Hospital Zurich supported the Graubuenden Cantonal
Hospital by the means of consultative treatment regarding an additional critically ill COVID–19 patient with CNS symptoms who had been admitted
there in the same time period. This case is also included in the study. The study was performed in accordance with the principles of the Declaration of
Helsinki and was approved by the local ethics committee (ID 2020–00894). Written consent was given by the legal representatives as all patients were
still incapable of judgment at hospital discharge.
Data Collection
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Severe cerebral disorders triggering the additional examinations such as cranial computed tomography (CT) or magnetic resonance imaging (MRI), EEG
as well as CSF analysis were: impaired consciousness (negative or delayed wake-up attempt after termination of analgosedation with persistent coma,
stupor or delirium), acute cerebrovascular disease, clinical seizure / status epilepticus and myoclonic movements. At time of neurological assessment,
midazolam serum levels were below the detection limit in all patients. SARS-CoV–2 infection was con rmed by reverse-transcription polymerase chain
reaction assay (RT-PCR) in throat and or tracheobronchial samples (according to (12) or by Roche Cobas SARS-CoV–2 test). Metagenomic virus
sequencing was performed as described (13). All examinations (laboratory values, chest radiographs and CTs) as well as neuroimaging, EEG and CSF
analysis were performed according to the clinical needs of the patients. Electronic medical records were reviewed for date of COVID–19 symptom
onset, neurological symptom onset, age, sex, pre-existing medical conditions (arterial hypertension, diabetes, smoking, cardiac disease, cerebrovascular
disease, immunosuppression because of malignancy or immunosuppressive treatment, lung disease, treatment with ACE inhibitors or angiotensin II
receptor antagonists, statins, anticoagulants) and speci c initial symptoms, especially anosmia/hyposmia, neuropsychiatric symptoms and focal
neurologic de cits. Data on empiric COVID–19 therapies (Hydroxychloroquine, Remdesivir) and pre-intubation worst oxygen saturation (SpO2) were
recorded. In addition to daily routine laboratory tests (blood cell counts, chemistry, coagulation testing) in patients with neurological de cits, serum was
analysed for glucose, lactate, immunoglobulins indices, interleukin–6, antinuclear antibodies (ANA), anti-neutrophil cytoplasmic antibodies (ANCA),
antibody to native DNA (nDNA), lupus anticoagulant, anti-cardiolipin, anti-β2-glycoprotein I, anti-SSA/Ro, anti-SSB/La and anti-IgLON5 antibodies.
Patient serum was tested for antibodies for viral infections (including SARS-CoV–2, herpes simplex virus (HSV), varizella zoster virus (VZV), cytomegaly
virus (CMV), hepatitis B virus (HBV) and human immunode ciency virus (HIV)). Laboratory values on the day of CSF sampling or the day before were
analysed. CSF samples were analysed for cell count (white and red cells) and cell composition, chemistry (glucose, lactate and protein), bacterial
culture, neurotropic viruses using RT-PCR to detect HSV, VZV, CMV and SARS-CoV–2 and immunology parameters including oligoclonal bands, total
CSF/serum IgG-, IgA- and IgM quotients as well as SARS-CoV–2-, HSV1-, CMV-, VZV-speci c and anti-IgLON5 antibodies. SARS-CoV–2 antibodies in
serum and CSF were tested using an in-house developed, bead-based antibody assay using Luminex that detects IgG, IgA and IgM antibodies against
subunit 1 (S1) and subunit 2 (S2) of the spike protein and nucleoprotein (NP) of SARS-CoV–2. Mean  uorescence intensity (MFI) was assessed using
FLEXMAP 3D (Luminex). Antibody reactivity was assessed in arbitrary units (AU) using a standard curve obtained from a serial dilution of the
respective standard serum for interpolating MFIs by four parameter logistic curve  t. AUs within the linear part of the standard curve were multiplied by
the corresponding dilution factor to obtain absolute AU. To calculate intrathecal SARS-CoV–2-, HSV1-, CMV-, and VZV-speci c IgG synthesis, the
antigen-speci c CSF/serum antibody index (CAIspec) was calculated according to (14).
We recorded 20 minutes EEGs using standard 25 channel montage (10/20). Electrophysiological analysis included visual scoring for epileptic activity,
vigilance, background activity, focal slowing and quantitative spectral analysis. We performed standardized painful and acoustic stimuli to test for EEG
reactivity in all patients.
CT neuroimaging was performed on a various scanner systems: SOMATOM Force, X.cite, De nition, and Edge plus, Siemens Healthineers, Forchheim,
Germany. MRI was performed on 3.0 Tesla scanners (either Ingenia; Philips, Eindhoven, The Netherlands, or Skyra, Siemens Healthineers, Forchheim,
Germany). The standard imaging protocol included axial T2-weighted (w), diffusion-weighted images (DWI) with b1000 m s/mm2, apparent diffusion
coe cient (ADC) map images, and susceptibility weighted imaging (SWI) sequences. Furthermore, 3D T1-weighted (non-contrast and contrast
enhanced) as well as 3D  uid attenuated inversion recovery (FLARI) sequences were acquired, each with axial, coronal and sagittal reconstructions.
Intracranial MRI vessel wall imaging was performed in three patients using high resolution T1w dark blood non-contrast and contrast enhanced space
sequences (Skyra, Siemens Healthineers, Forchheim, Germany).
Statistical Analysis
Descriptive statistics and frequency analysis are calculated to describe characteristics of the study sample and overall prevalence of concomitant
factors. Mean and standard deviation (SD) are used for normally distributed data and median and range for data that were not normally distributed.
Categorical variables are expressed as counts and percentages. The time from onset of the  rst symptoms of COVID–19 to manifestation of CNS
symptoms was calculated in days.
Results
Demographic and Clinical Characteristics
Among 32 critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV–2) infection eight patients (18%) presented with
severe CNS involvement. Their mean (SD) age was 67.6 (6.8) years, seven were male. Two patients died due to respiratory or multiorgan failure.
Baseline characteristics are given in Table 1. All patients had cardiovascular risk factors, most frequently hypertension as a pre-existing condition. The
characteristics of the patients during the course of the disease are given in Table 2. All patients were treated with invasive mechanical ventilation and
all but one with prone positioning. Seven had to be treated with continuous renal replacement therapy due to renal failure. Three patients suffered from
myocardial injury characterized by elevated troponin, myoglobin and creatinine phosphokinase (patients 1,2 and 6) and one from acute mesenteric
ischemia requiring surgery and leading to multiorgan failure (patient 1).
Clinical and Neuroradiological Characteristics
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CNS symptoms became manifest on day 17.5 in median (range day 2 to 34). In no patient anosmia/hyposmia or neuropsychiatric symptoms could be
revealed in the medical history. In two patients (patients 6 and 7), CNS symptoms included primary focal neurological de cits due to an ischemic
stroke, in one of them manifesting before pneumonia became evident (patient 7). In both patients single lacunar ischemic lesions corresponding to
their primary focal neurological de cits were present in the initial CT. Their follow-up MRI scans showed additional small ischemic lesions in different
vascular territories. All but one patient (patients 1, 2, 4, 5, 6, 7 and 8) presented with impaired consciousness for several days after termination of
analgosedation. In all but two patients (patients 3 and 4), CT or MRI scans performed later in the course of the disease, showed multiple cerebral
microbleeds, in three of them with additional subarachnoid haemorrhage (patients 1, 2 and 8) (Figure 1). Three patients were examined with
intracranial vessel wall sequence MRI (patients 2, 6 and 7). In all three patients vessel wall contrast enhancement of large to middle-sized cerebral
arteries was found (Figure 2).
One patient was admitted from a peripheral hospital due to status epilepticus (patient 3) which was successfully treated with levetiracetam and
valproate. Thereupon pronounced myoclonic movement patterns occurred on all extremities. Except generalized brain atrophy, CT and MRI scans
showed no abnormal  ndings.
Laboratory Findings
Laboratory  ndings are given in table 3. At time of CNS symptoms the median values for lymphocyte count were 1.84 x 109G/L (range 1.03 to 2.47 109
G/L), CRP 87 mg/L (range 8 to 240 mg/L), IL–6 48.5 ng/L (range 6.4 to 594 ng/L),  brinogen 5.8 g/L (range from 4.5 to 8.1 g/L) and D-dimer 6.45
mg/L (range from 2.6 to 20 mg/L).Autoantibodies such as ANA, ANCA, anti-dsDNA, anti-cardiolipin, anti- β2-glycoprotein as well as lupus anticoagulant
were negative in patient 5 and 7, in patient 6 only the unspeci c IgA antibodies for anti-cardiolipin and, anti-β2-glycoprotein, as well as and ANA were
slightly elevated.
CSF could be analysed in seven patients. 2 days (range 0—31) after  rst observation of CNS symptoms after analgosedation and 17.5 days (range 2—
34) after onset of COVID–19 pneumonia. Cell counts as well as chemistry (except slightly elevated proteins in patients 3 and 5) were normal in all
patients. All CSF samples probed negative for SARS-CoV–2 and other neurotropic viruses. While SARS-CoV–2 IgG was present in serum of all patients,
no intrathecal SARS-CoV–2 IgG synthesis was detectable. In two patients (patients 3, 7 and 8) metagenomic virus sequencing from CSF resulted in
negative  ndings.
EEG Findings
All patients showed similar, yet unspeci c EEG patterns with severe to moderate background slowing and anterior rhythmic delta activity consistent
with metabolic encephalopathy. No interictal epileptiform discharges were found. However, we found stimulus induced periodic discharges (patient 5)
and rhythmic frontal theta activity in myoclonic status (patient 2) as a correlate for enhanced epileptogenicity.
Autopsy Findings
Brain autopsy of one patient (patient 1) showed acute microbleeds in the pontine tegmentum and acute microinfarcts in the basal ganglia. Around the
rostral surface of the cerebellum an extensive, acute subarachnoidal haemorrhage was seen. Adjacent cerebral tissue showed multiple fresh, partially
con uent, microinfarcts and parenchymal haemorrhages. In addition, fresh blood was found in the perihippocampal area.
Outcome
At time of submission all six surviving patients were still hospitalized but showed signi cant neurological recovery (three with still mild cognitive
de cits, two with slight to moderate tetraparesis indicating critical illness neuro- and myopathy, one with persistent myoclonic movements). The two
stroke patients showed no focal neurological de cits anymore.
Discussion
In the Wuhan series, 27 of 88 patients hospitalized with severe COVID–19 infection (30.7%) had CNS symptoms (1). 13 of them (48.1%) suffered from
impaired consciousness,  ve from acute cerebrovascular disease (18.5%), one from ataxia and one from seizure. Neurological features were found in
58 of 64 consecutive hospitalized patients in Strasbourg (4). Most of them occurred when sedation was withheld (67%) and consisted of agitation
(69%), confusion (65%) and diffuse corticospinal tract signs (67%).
In the present patient population of 32 ICU patients with COVID–19, eight (25%) had severe CNS symptoms, among them two with hemiparesis and
lacunar ischemic stroke and one with status epilepticus in the early phase. As most common presentation, six patients presented with prolonged
impaired consciousness after termination of analgosedation, three with temporarily delirious state.
The different patterns of our cases suggest that variable pathogenesis may lead to CNS disorders in COVID–19. Evaluating and summarizing the
published small series and individual cases (1–3, 5–11), neurologic sequelae can be assigned to the following pathophysiological groups:
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Unspeci c, related to severity of disease
In one case hypoxic encephalopathy, presenting as status epilepticus and myoclonic movements, and in another case, metabolic-toxic encephalopathy,
associated with uraemia, might be unspeci c cerebral complications in two of our critically ill COVID–19 patients. In both patients neuroimaging
showed no speci c  ndings but frontotemporal brain atrophy, which might be associated with sepsis-induced brain dysfunction (15). Sepsis-
associated encephalopathy, which typically presents as confusion and coma, is reported in up to 70% of patients with sepsis (16). All our patients’ EEG
examinations showed severe generalized background slowing, indicating global cognitive dysfunction and occurring in patients after recovery from
severe sepsis (17). In the Beijing series, critically ill COVID–19 patients developing septic shock and multiorgan failure have been described (18). In 76%
of the cases cultures for bacteria and fungus were negative. The authors, therefore, used the term “viral sepsis”. As in sepsis induced by other
microorganisms, hyperactivation of proin ammatory cytokines and chemokines play an important role in severe COVID–19 and may be associated
with septic encephalopathy. Finally, epileptic activity seems to occur only rarely in COVID–19 patients (0.5% in the Wuhan series) (1) and might be
related to hypoxia, multiorgan failure, and metabolic disorder rather than to CNS infection (19). In agreement, also in our series the occurrence of
epileptic activity and myoclonic status in patient 3 was most probably caused by hypoxic brain injury.
Large and small cerebral vessel disease
Two of our patients presented with acute ischemic stroke in the early phase of their disease. A series of  ve cases of large -vessel stroke in patients
younger than 50 years has been described in New York City (6). In the Wuhan series, the incidence of stroke in hospitalized patients was about 5% (1).
Severe infections, especially respiratory-related, are known to trigger acute cerebrovascular events (20). Severe COVID–19 mostly develops in patients
with cardiovascular risk factors and is characterized by a pronounced proin ammatory early phase (18), both factors even aggravating the risk for
stroke at disease onset. In Strasbourg, 23 patients with neurological symptoms were examined with MR imaging (4). Three asymptomatic patients had
small ischemic strokes and bilateral frontotemporal hypoperfusion was noted in all 11 patients who underwent perfusion imaging (4). Contrast -
enhanced perfusion MR was not performed in our series. However, the unspeci c EEG patterns in our patients with background slowing and occasional
anterior rhythmic delta activity, consistent with unspeci c encephalopathy, might also re ect frontal hypoperfusion.
Further extraordinary  ndings in our series were detected later in the course of the disease. In all but one patient with delayed wake-up, neuroimaging or
autopsy showed multiple cerebral microbleeds, in three of them with additional subarachnoid haemorrhage and in another two with additional small
ischemic lesions, indicating CNS small vessel disease. Different factors might explain the involvement of small cerebral vessels. All patients had
cardiovascular risk factors, most of them hypertension. The distribution of the microbleeds, however, was typical for hypertension in only one patient.
None of our patients had a history of cerebral amyloid angiopathy. As in other series, all our patients had a hypercoagulable state with increased
 brinogen and D-dimer levels (11, 21), which might lead to thrombosis of small cerebral vessels. Only one patient, however, ful lled the criteria of
disseminated intravascular coagulation disorder (> 5 points according to the International Society on Thrombosis and Haemostasis criteria) (22), which
is known to be associated with acute cerebral micro-angiopathy. Immune-mediated and infectious vasculitis may cause CNS small vessel disease (23)
and a certain type of vasculitis involving cerebral vessels might be induced by COVID–19 as well.
In three patients with severe COVID–19 intracranial vessel wall sequence MRI scans were performed, for the  rst time to our knowledge. MR vessel wall
imaging showed contrast -enhancement of vessel walls in large and middle-sized cerebral arteries, suggesting vascular wall pathologies with an
in ammatory component. However, MRI vessel wall contrast- enhancement is not speci c for vasculitis involving cerebral vessels. None of our patients
showed in ammatory signs in the CSF or characteristic autoantibodies indicating systemic vasculitis. Chen et al. found vessel wall contrast -
enhancement in 45.8% of the patients with reversible cerebral vasoconstriction syndrome (RCVS) (24). The authors suggest that, among other factors,
endothelial dysfunction might contribute to vascular wall in ammation in RCVS. However, none of our patients had typical signs of RCVS such as
thunderclap headache and/or reversible multifocal cerebral vasoconstrictions.
Contrast -enhancement of vessel walls as well as the pattern of micro-bleedings and multiple small infarctions indicate that large, middle-sized as well
as small cerebral vessels are involved. An autopsy study in patients with severe COVID–19 revealed vascular involvement in multiple organs (25).
Lymphocytic endotheliitis was found in lung, heart, kidney, liver and small intestine. Furthermore, viral inclusion structures, could be found in endothelial
cells. The angiotensin-converting enzyme 2 (ACE2), as the main host cell receptor of SARS-CoV–2 (26), albeit at lower concentrations, is also expressed
in the endothelium and vascular smooth muscle cells of the brain (27). It might be hypothesized that the endothelium of brain vessels might be directly
affected by the virus or that the virus induces a parainfectious immune-mediated in ammation of the endothelium. However, we did not  nd any
in ammatory CSF syndrome as a sign of infectious cerebral vasculitis in our patients or signs of perivascular in ammatory cell in ltration in the one
post-mortem analysis performed. Another mechanism might be, that the cerebral vessels might be affected by the in ammatory state in the peripheral
blood. Prolonged increased levels of IL–6, IL–10, IL–2 and IFN γ have been described in severe cases and may play an important role in the
immunopathology of COVID–19 (28). In our patients, serum IL–6 was elevated in all but one patient up to levels of 594 ng/L. However, in all of them
IL–6 values in the serum were higher than in CSF, which contradicts its intrathecal synthesis. Still, these observations do not exclude the possibility of
damage to cerebral vessels induced by the hyperin ammatory state in the peripheral blood. Cytokines or in ammation-induced metabolic changes
leaking from peripheral blood to the CNS micromilieu might lead to disseminated focal disturbances of the blood brain barrier and dysfunction of the
respective surrounding brain tissue.
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Encephalitis
Singles cases with COVID–19 and meningo-encephalitis, one case with acute necrotizing encephalopathy and one with acute disseminated
encephalomyelitis (ADEM) have been described (2, 3, 5, 7–11). Neuroinvasion is hypothesized to occur via hematogenous or neuronal route as over the
olfactory nerve (29). In two cases with neuropsychological symptoms, one of them with status epilepticus, lymphocytic pleocytosis but negative RT-
PCR for SARS-CoV–2 was found in the CSF (2). In another case suffering from disorientation and hallucinations, CSF analysis also revealed
lymphocytosis (3). To our knowledge, up to date, gene sequencing con rmed the presence of SARS-CoV–2 in the CSF in Beijing in only one case (30)
and RT-PCR was positive in only one patient in Japan (5). None of our patients, not even those with status epilepticus, showed in ammatory signs
neither in neuroimaging nor in the CSF. RT-PCR for SARS-CoV–2 in the CSF was negative in all patients. Intrathecal IgG production against the SARS-
CoV–2 could not be demonstrated and even metagenomic virus sequencing was negative in two patients. Therefore, neither direct neuroinvasive
potential nor directly CNS-directed parainfectious injury could be demonstrated in our patients.
Limitations
Only eight patients were studied. All were severely ill, entering the ICU with respiratory failure. Mild neurological symptoms at disease onset as
headache, dizziness and taste or smell impairment could no longer be reliably evaluated. Furthermore, CNS symptoms might have remained undetected
in patients who were under analgosedation. Diagnostics with neuroimaging and CSF analysis might not have been performed at the time of the
occurrence of cerebral complications. Therefore, in ammatory signs in the CSF, might have been missed. Furthermore, RT-PCR tests for SARS-CoV–2 in
the CSF are not yet su ciently clinically validated regarding sensitivity and timing of lumbar puncture after onset of symptoms. We cannot exclude the
possibilities of (i) transient SARS-CoV–2 RT-PCR positivity in the CSF through true invasion of CNS with SARS-CoV–2, which turned out to be negative
at the time of lumbar puncture, or (ii) concentrations of SARS-CoV–2 in the CSF below detection limit of our RT-PCR assay. Additional search for
intrathecal SARS-CoV–2-speci c IgG production as a sign of humoral immune reaction against viral infection of CSF space turned out negative. In
other viral CNS infections such as herpes encephalitis or tick-borne encephalitis, intrathecal antiviral IgG production usually consistently occurs 10–14
days after onset of symptoms, but may occur occasionally as early as 3 days after disease onset (31–33). Our observation of no intrathecal SARS-
CoV–2 IgG production may be explained by the possibilities, that SARS-CoV–2 never entered CNS and therefore no intrathecal immune response was
mounted or because intrathecal SARS-CoV–2-speci c IgG synthesis occurred after lumbar puncture. In analogy to other human viral CNS infections, the
consistent combination of negative SARS-CoV–2 RT-PCR and absence of intrathecal SARS-CoV–2 IgG production 2 days (range 0—31) after onset of
CNS disorder argues relatively against a direct invasion of CNS by SARS-CoV–2, but we cannot exclude the possibility of a differential diagnostic
window, which might have been missed.
Conclusions
Severe CNS disorders are common in patients with severe COVID–19 and different pathomechanisms might be involved. Besides unspeci c
encephalopathic patterns and encephalitic syndromes described as case reports, large vessel strokes might occur more often early after disease onset.
In a later phase, microbleeds and microinfarctions as well as vessel wall contrast enhancement occur, indicating large and small cerebral vessels to be
involved. Patients with endothelial dysfunction due to cardiovascular risk factors, mostly hypertension, might be especially at risk. Whether SARS-CoV–
2 directly affects endothelial cells of brain vessels has to be investigated in basic research and more clinical cases. CNS disorders associated with
COVID–19 can lead to long-term disabilities and may aggravate socio-economic damage. The mechanisms have to be investigated urgently in order to
develop preventive and therapeutic neuroprotective strategies.
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Tables
Table 1: Baseline Characteristics of Patients with CNS manifestationsCharacteristics No.Mean age, years (SD) 67.6 (6.8)Sex  Female 1Male 7Pre-existing comorbidities  Arterial hypertension 7Diabetes 6Smoking 0Obesity 2Hypercholesterolemia 1Cardiac disease 1Cerebrovascular disease 1Immunosuppressed state 1Lung disease 1Others 1Pre-existing medication  ACE-Inhibitors or angiotensin -II -receptor antagonists 4Statins 2Initial presentation  Pneumonia 8Ischemic stroke 1CNS manifestation  Delayed wake-up 7Ischemic stroke 2Status epilepticus 1Myoclonic movements 2Pupil disturbances 2
 Abbreviations: CNS, central nervous system
  
Table 2: Characteristics of Patients with CNS disorders in the Course of the Disease
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Variable Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8Age, y 58 68 66 81 65 66 75 62Sex Female Male Male Male Male Male Male MaleCardiovascularrisk factors Hypertension,diabetes,obesity






Amlodipine,Metformin Sick sinussyndrome,chronic venousinsufficiency
Rosuvastatin
EmpiricCOVID-19 treatment
Hydroxychloro-quine Hydroxychloro-quine None Hydroxychloro-quine None None Hydroxychloro-quine Hydroxychloro-quine
Pre-intubation/worst SPO2, % 68 89 Cyanosis atemergencyintubation
83 86 93 85 90









CNS disorder Negative wake-up, non-reactive pupilsafter CPR
Delayed wake-up, myoclonicmovements,later delirium
Statusepilepticus,myoclonicmovements
Negative wake-up,pathologicalbreathingpattern
Delayed wake-up Acute leftischemicstroke (righthemiparesisdysarthria),delayed wake-up









Time fromdisease onsetto first CNSsymptoms
17 25 16 18 34 2  (primarydiagnosisstroke)
17 22
Neuroimaging CT: acutebilateralcerebellarsubarachnoidhaemorrhage 
CT: acutesubarachnoidhaemorrhageright frontallobe, focalbrain swellingMRI: minorsubarachnoidhaemorrhageon variousbilaterallocations. MRI(VWI): vesselwallenhancementleft MCA, rightPCA
CT and MRI:no acutefindings,frontotemporalbrain atrophy
CT: no acutefindings,frontotemporalbrain atrophy,high-gradestenosis ofright internalcarotid artery
CT: no relevantfindingsMRI: threemicrobleedswith unspecificdistribution(parietal lobe,right temporallobe)
CT(admission):leftlenticulostrialinfarction,distal stenosisof M1 segmentleft MCAMRI (followup): multiplebilateral earlysubacuteischemiclesions indifferentvascularterritories,ubiquitousmicrobleeds,i.a. bi-thalamic,corpuscallosum,periphery MRI (follow-upVWI): Markedbilateral vesselwallenhancement  
CT(admission):acute ischemiclesion leftprecentralgyrus,microbleedsright centrumsemiovale,right superiorfrontal gyrusMRI (followup): multiplebilateral smallearly subacuteischemiclesions in bothMCAterritories,microbleeds inatypicallocations MRI (follow-upVWI): markedvessel wallenhancementright MCA
CT: Rightfrontalsubarachnoidhaemorrhagewith frontallobe swelling,minorintraventricularbloodbilaterally MRI: Additionalminor leftfrontal andright parietalsubarachnoidhaemorrhage,supra- andinfratentorialmicrobleedswith apredominantlyhypertensionrelated pattern








reactivity topain: noneEEG follow-up(+5d):persistentdiffusebackgroundslowing(Theta)
artefacts dueto myoclonicstatusepilepticus.Reactivity topain: none 
Reactivity topain: yes(backgroundactivation).  
Reactivity topain: yes(backgroundactivation). Follow-up(+6d): backgroundslowing.Periodicdischarges onstimulus(SIRPIDS)  
(theta/delta).FIRDA. Reactivity topain: yes(backgroundactivation). Follow-Up(+14d): mildbackgroundslowing(Theta). 
reactivity topain: yes(backgroundactivation) 
and burstsuppressions)
Type of CNSdisorder Small vesseldisease Small vesseldisease Hypoxiainduced Metabolic/-toxic Small vesseldisease Large andsmall vesseldisease
Large andsmall vesseldisease
Small vesseldisease







CNS, central nervous system; CPR, cardiopulmonary reanimation; CSF, cerebrospinal fluid; CT, computed tomography; ECMO, extracorporeal membraneoxygenation; EEG, electroencephalography; FIRDA, frontal intermittent rhythmic delta activity, HIT, heparin induced thrombocytopenia; ICU, intensive care unit;IMV, invasive mechanical ventilation; MCA, middle cerebral artery; MRI, magnetic resonance imaging; NA, not available; PCA, posterior cerebral artery; SIRDIPSstimulus-induced rhythmic periodic, or ictal discharges; SPO2, oxygen saturation; VWI, intracranial vessel wall sequence MRI; * Concomitant condition: additionalfindings which occurred at the time of the neurological deficits
 
 Table 3: Laboratory Findings of Patients with CNS disorders in the Course of the Disease
Variable Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8Relevantpathologicallaboratoryvalues at timeof CNSdisorder
Lymph 1.82 /L,CRP 83 mg/L,IL-6 594 ng/L,fibrinogen 6.3g/L, D-dimer >20mg/L,thromb 96 /L
Lymph 2.47 /L,CRP 32 mg/L,IL-6 24.1 ng/L,fibrinogen 5.8g/L, D-dimer3.38 mg/L
Lymph 1.12 /L,CRP 29 mg/L,IL-6 15.2 ng/L,fibrinogen 5.2g/L, D-dimer8.59 mg/L 
Lymph 3.3 /L,CRP 116.0mg/L, IL-6 73.0ng/L,fibrinogen 8.1g/L, D-dimer5.01 mg/L,thromb 83 /L,creatinine 353umol/L, urea30.1 mmol/L
Lymph 1.03 /L,CRP 121.0mg/L, IL-6 131.8 ng/L,fibrinogen 5.4g/L, D-dimer14.59 mg/L
Lymph 1.22 /l,CRP 91.0mg/L, IL-6 85.2ng/L,fibrinogen6.3g/L, D-dimer 5.05mg/L
Lymph 1.86 /L,CRP 8.0 mg/L,IL-6 6.4 ng/L,fibrinogen 4.5g/L, D-dimer7.86 mg/L
Lymph 2.25 /L,CRP 240 mg/L,IL-6 21 ng/L,fibrinogen 5.8g/L, D-dimer2.6 mg/L
DIC score * 6 2 2 3 3 2 2 3Time from first CNSsymptoms tolumbarpuncture
2 1 6 2 3 31 0 2
CSF mainfindings NA Cell count 1/ul,normalchemistry,SARS-CoV2RT-PCRnegative, nointrathecalSARS-CoV2IgG synthesis,IL-6 in CSF <IL-6 serum
Cell count 1/ul,protein 845mg/l, albumin392 mg/l,SARS-CoV2RT-PCRnegative, nointrathecalSARS-CoV2IgG synthesis,IL-6 in CSF <IL-6 serum,viralmetagenomicanalysisnegative
Cell count 1/ul,normalchemistry,SARS-CoV2RT-PCRnegative, nointrathecalSARS-CoV2IgG synthesis,IL-6 in CSF <IL-6 serum
Cell count 2/ul,protein 731mg/l, SARS-CoV2 RT-PCRnegative, nointrathecalSARS-CoV2IgG synthesis,IL-6 in CSF <IL-6 serum
Cell count 1/ul,normalchemistry,SARS-CoV2RT-PCRnegative, nointrathecalSARS-CoV2IgG synthesis,IL-6 in CSF <IL-6 serum 
Cell count 0/ul,normalchemistry,SARS-CoV2 RT-PCR negative,no intrathecalSARS-CoV2 IgGsynthesis, IL-6in CSF < IL-6serum, viralmetagenomicanalysisnegative
Cell count 8/ul,SARS-CoV2 RT-PCR negative,no intrathecalCoV2 IgGsynthesis
Type of CNSdisorder Small vesseldisease Small vesseldisease Hypoxiainduced Metabolic/-toxic Small vesseldisease Large andsmall vesseldisease
Large andsmall vesseldisease
Small vesseldisease
CNS, central nervous system; CSF, cerebrospinal fluid; DIC, disseminated intravascular coagulopathy; Lymph, lymphocyte count inx109/L; NA, not available; thromb, thrombocyte count in x109/L
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* DIC score according to International Society on Thrombosis and Haemostasis CRRT continuous renal replacement therapy 
Figures
Figure 1
Illustration of the characteristic MRI  ndings in patient 2. Susceptibility-weighted imaging (SWI) shows subarachnoid haemorrhage on various bilateral
locations (A). Intracranial vessel wall imaging (VWI) demonstrates vessel wall contrast enhancement of the left MCA (B) and right PCA (C)
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Figure 2
Illustration of the characteristic MRI  ndings in patient 6. Diffusion weighted imaging (DWI) shows bilaterally multiple early sub-acute ischemic lesion
in different vascular territories (A) and ubiquitous microbleeds in susceptibility-weighted imaging (SWI) (B). Intracranial vessel wall imaging (VWI)
demonstrates vessel wall contrast enhancement of the left MCA (C)
